MedTrace Logo

Cell Therapy for Immunomodulation in Kidney Transplantation

NCT03867617 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-12-02

No results posted yet for this study

Summary

This study investigates treatment with recipient regulatory T cells and donor bone marrow together with tocilizumab for immunomodulation in living donor kidney transplant recipients.

Conditions

  • Kidney Transplantation

Interventions

OTHER

Regulatory T cells

Single infusion of expanded regulatory T cells.

DRUG

Tocilizumab

Treatment during first month post-transplant.

OTHER

Bone marrow

Infusion of donor bone marrow cells.

PROCEDURE

Kidney transplant

Living donor kidney transplantation.

OTHER

Immunosuppressive drug therapy

Immunosuppressive drug therapy.

Sponsors & Collaborators

  • University Hospital Regensburg

    collaborator OTHER

  • Thomas Wekerle

    lead OTHER

Principal Investigators

  • Thomas Wekerle, MD · Medical University of Vienna

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-01
Primary Completion
2024-06-30
Completion
2028-06-30

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03867617 on ClinicalTrials.gov